Fc receptor homologs are a recently identified family of proteins homologous to FcgRI, found on human and mouse B cells. One of these, FREB/FcRX/FCRL, was found to be unique since it lacks a transmembrane domain and is expressed intracellularly within germinal center B cells. We have identified in humans and mice a new Fc receptor homolog, FREB2, that blends conserved elements of the classical Fc gamma receptors with structural motifs previously thought to be unique to FREB1. This protein is comprised of three immunoglobulin-like domains with high homology to those in FcgRI, and a C-terminus containing a proline-rich stalk region followed by a leucine-rich amphipathic alpha helix. Like FREB1, FREB2 is expressed as an intracellular protein. In murine splenocytes, RNA transcripts for each of the two proteins can be amplified from germinal center B cells. However, immunohistochemical analysis of human tonsils indicates that expression of FREB1 and FREB2 is mutually exclusive in non-neoplastic cells. Importantly, FREB2 expression within human tonsils appears to be limited to a small subset of nonproliferating germinal center B cells, suggesting that it may play a role in regulating clonal expansion or differentiation of B cells during the germinal center reaction.
Introduction
Fc receptors are immunoglobulin-binding receptors expressed on cells of both hematopoietic and nonhematopoietic origin. Their functions can be characterized broadly to include cellular activation and regulation, immunoglobulin transport, and immune complex retention. 1, 2 Recently, a group of six receptors homologous to FcgRI has been identified and found to be preferentially expressed by B cells at various stages of differentiation. Five of these Fc receptor homologs were concurrently identified and share many similar structural elements. All are type I transmembrane proteins of the immunoglobulin superfamily, and display potential immunoreceptor tyrosine-based activation and/or inhibitory motifs (ITAMs or ITIMs) in their cytoplasmic domains. [3] [4] [5] [6] [7] [8] [9] [10] [11] IRTA1/FcRH4/IFGP2 was originally identified as part of an Ig-Ca1 fusion protein resulting from the translocation of chromosome 1q21 with 14q32 in a human multiple myeloma cell line. Expression of this gene was found to be localized within naïve and memory B cells of the marginal zone and epithelium. More recent analysis of the cytoplasmic domain of this protein has indicated that it is likely to function as a potent inhibitory receptor for regulating memory B-cell activation. 4, [6] [7] [8] 12, 13 A second homologous cDNA encoding IRTA2/FcRH5/ BXMAS1 was cloned and found to be dysregulated in Burkitt's lymphoma cell lines with 1q21 abnormalities. Transcript for this gene can be detected within naïve B cells, memory, and plasma cells of the mantle zone, interfollicular, intraepithelial, and germinal center light zones. 3, 4, [7] [8] [9] Three additional members of this family, FcRH1-3 (also designated IRTA5/IFGP1, IRTA4/SPAP1/ IFGP4, and IRTA3/SPAP2/IFGP3, respectively), were identified in both humans and mice, and found to be expressed in naïve B cells of the mantle zone, interfollicular memory B cells, and B cells of the germinal center light zone. While most Fc receptor homologs contain potential ITAM or ITIM motifs, one of these, FcRH1, contains only ITAM-like motifs in its cytoplasmic tail, and has been implicated as a possible coreceptor for B-cell activation. [3] [4] [5] [6] 8, 10, 11, 14 The sixth FcR homolog, FREB1/FcRx/FCRL, was found to be unique among these FcR homologs in a number of ways. In the place of a transmembrane domain and signaling motifs, FREB1 was found to contain a unique proline-rich sequence and leucine-rich helical motif in its C-terminus. Also, FREB1 expression was found to be exclusively intracellular, and largely within proliferating cells of germinal center, or within splenic marginal zone lymphocytes. These unique attributes suggested a novel role for FREB1 in the development of B-cell responses. [15] [16] [17] [18] Like other Fc receptor homologs, expression of FREB1 within B-cell neoplasms is widespread, with particularly high abundance in small lymphocytic, follicular, marginal zone, lymphoplasmacytic, and diffuse large B-cell lymphomas, as well as lymphocyte-predominant Hodgkin's disease. 15, 18 The abundance of FREB1 within B-cell tumors is suggestive that it may be beneficial diagnostic or prognostic indicators for treating lymphoma. For FREB1, this idea has been strengthened by the recent observation that FREB1 is expressed at significantly higher levels in Rituximab-responsive follicular lymphomas vs nonresponders. 19 The existence of genes encoding other Fc receptor homologs in addition to these has been predicted. 3, 16 In this study, we have identified a new Fc receptor homolog, FREB2, with immunoglobulin domains homologous to FcgRI, and a C-terminal domain previously thought to be unique to FREB1. Its expression within nonproliferating cells of the germinal center suggests a unique role for this protein in regulating B-cell differentiation. out on mouse tissues was performed using the methods described in the previous section.
Materials and methods

Cloning
Immunofluorescence of transfected cells Human FREB2 was cloned into the mammalian expression vector pcDNA3.1 and transfected transiently into 293T cells using Lipofectamine 2000 reagent according to vendor-supplied protocols (Invitrogen). Cells were fixed with 2% paraformaldehyde in PBS and permeabilized in saponin buffer (PBS/0.5% saponin/5% bovine calf serum). Cells were stained with antiserum specific for the human FREB2 peptide TSHFAVSPGTPETTPVES (Biosource Int.) followed by goat anti-rabbit IgG Alexafluor 555 (Molecular Probes). For visualization, cells were counter-stained with Phalloidin-Oregon green (Molecular Probes) to label filamentous actin and the nuclear stain DAPI (Vector Labs).
Histological analysis of FREB2 expression in human tonsils
Human tonsils were frozen in OCT compound, and 5 mM cryosections were stained with FREB2-specific rabbit antisera. Staining was visualized by fluorescence microscopy using polyclonal goat anti-rabbit IgG conjugated to either Alexafluor 488 or 555 (Molecular Probes). FREB2 was counter-stained with the nuclear stain DAPI (Vector Labs) and antibodies specific for human IgG, IgA, IgM, IgD, CD38, CD56 (Pharmingen), CD3, CD4, CD8, CD19, and Ki67 (Immunotech).
Results
FREB2 is a member of the immunoglobulin superfamily homologous to FccRI and FREB1
A query of the NCBI mouse genome database for molecules homologous to FREB1 using the tBLASTN algorithm resulted in the identification of a putative transcript encoded approximately 12 kb from FREB1 on mouse chromosome 1. Sequence analysis of potential open-reading frames indicated that this molecule was another potential Fc receptor homolog. Subsequent cloning and sequencing of this molecule from the spleens of immunized mice indicated that this molecule did indeed share important sequence features with the highaffinity immunoglobulin receptor FcgRI, as well as some structural motifs previously thought to be unique to FREB1. The cDNA sequence of this new mouse gene was compared against human genomic DNA and EST databases to determine the likely sequence of the human ortholog, which was then cloned from the Burkitt's lymphoma cell line Raji by RT-PCR. Owing to its aminoacid sequence similarity with FcgRI and FREB1, and its apparent expression by B-cell lymphomas, it was designated FREB2. Based on sequence features and genomic position, the gene encoding FREB2 is likely to be the gene predicted to exist and given the names FcRY 3 or FCRL2. 16 The cDNA and amino-acid sequences of human and mouse FREB2 are listed in Genbank under accession numbers AY786314 and AY513660.
The amino-acid sequence of FREB2 is encoded by six exons. As with other Fc receptor homologs, the leader peptide is encoded within the first two exons. Each of the three immunoglobulin-like domains is encoded by a single exon, and the last exon encodes a domain with proline and leucine-rich sequences. The three immunoglobulin domains share 38% sequence identity with those in FcgRI, and contain the motif WLILQ-X 18 -W, found at the junction of the first two immunoglobulin domains in FcgRI, FcgRII, FcgRIII, and FceRI. In total, FREB2 conserves 11 of 15 residues that have been identified in structural studies as important for immunoglobulin binding by other classical Fc receptors. 20 The C-terminus of FREB2 displays striking similarities to the C-terminus of FREB1. It contains no transmembrane domain, but instead has a leucine-rich region that is likely to form an amphipathic alpha helix, and may function in protein-protein interactions. Linking the leucine-rich helix to the immunoglobulin domains is a proline-rich peptide, which may function as a flexible stalk region for the molecule. As with FREB1, the aminoacid sequence of FREB2 is highly conserved among mammals. Comparison of human and mouse FREB2 sequences shows 82% identity, with the highest degree of conservation found in the immunoglobulin domains and leucine-rich region (Figure 1b) . While FREB1 and FREB2 share many structural features, their actual amino-acid sequences are somewhat divergent. The two molecules have only 26% amino-acid identity, nearly all of which is found within the second and third immunoglobulin domains, and the leucine-rich helix. One last notable feature of the FREB2 sequence is the presence of an unpaired cysteine residue in the proline-rich region of the C-terminus. The presence of this unpaired cysteine in close proximity to the leucine-rich coiled-coil motif suggests possible covalent homotypic or heterotypic interactions between FREB2 and another protein.
FREB2 transcript is expressed in lymphoid and nonlymphoid tissues FREB2 transcript is extremely rare, and is often detectable in cells and tissues only through nested RT-PCR. In humans, FREB2 expression was detected after a single round of PCR from the kidney, placenta, and spleen cDNA (Figure 2) . With an additional 35 cycles of amplification using nested primers, it was also possible to detect FREB2 transcript in the peripheral blood leukocytes, heart, lung, liver, pancreas, thymus, prostate, testis, ovary, and small intestine (data not shown). However, with this level of sensitivity, it is not clear whether this signal reflects expression of FREB2 within those tissues, or whether contaminating peripheral blood leukocytes result in the presence of FREB2 transcript. In tissues from immunized mice, nested RT-PCR can regularly detect FREB2 transcript in the spleen, lymph node, and kidney. Transcript was also often detected in the lung and brain (data not shown). However, efforts to compare relative levels of FREB2 transcript in tissues by Northern blot analysis were unsuccessful, most likely due to the rarity of transcript.
In order to determine which lymphoid cell types expressed FREB2, splenocytes from mice immunized with NP-KLH were FACS sorted into discrete subsets. RNA was isolated from the sorted populations and nested RT-PCR was performed to detect FREB2 transcript. 
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Staining of human tonsils with a polyclonal rabbit antiserum specific for the C-terminus of FREB2 showed FREB2 expression in a small subset of germinal center B cells ( Figure 5 ). Morphologically, these cells are very small, with very little cytoplasm surrounding the nucleus, and are distributed somewhat stochastically throughout the germinal center. They seem to express little or no surface immunoglobulin, but retain expression of CD38 at a low level. Interestingly, although FREB1 and FREB2 share similar structural features and are generally expressed in the same follicular zones, costaining of human tonsils with antibodies specific for FREB1 and FREB2 showed that their expression at the cellular level is nearly always mutually exclusive. Whereas FREB1 is generally found in proliferating cells of the germinal center and extrafollicular B cells, FREB2 expression was found to be localized within nonproliferating (Ki67-negative) cells of the germinal center. FREB2-positive cells outside the germinal center were extremely rare. FREB2 localization within CD3 þ , CD4 þ , or CD8 þ T cells or CD56 þ NK cells was not observed.
Discussion
Here, we have reported the molecular cloning and initial characterization of human and mouse FREB2, the newest member of the extended Fc receptor family. Structurally, this protein blends characteristics found in the classical high-affinity immunoglobulin receptors with the unusual C-terminal motifs previously found only in FREB1. The amino-acid sequence of the three immunoglobulin domains of FREB2 bears significant resemblance to those of FcgRI, including the positioning of residues contributing to the high-affinity interaction between other classical Fc receptors and IgG or IgE. This strongly suggests that this molecule binds to immunoglobulins. However, this interaction has yet to be experimentally established. As discussed previously, the C-terminus of this molecule bears resemblance to that of FREB1. Within this C-terminal domain is a proline-rich region that most likely forms a flexible stalk linking the Ig domains to the leucine-rich helix at the C-terminus of the molecule. The leucine-rich region is likely to form an amphipathic coiled-coil motif that may mediate homotypic or heterotypic interactions between FREB2 and another protein.
Such an interaction may be further stabilized by disulfide linkage through the unpaired cysteine residue located N-terminal to the leucine-rich region. FREB2 transcript is extremely rare, and thus is generally only detectable by PCR. Within sorted cell populations, nested PCR is often required to detect transcript. In murine splenocytes, FREB2 transcript can be detected by nested RT-PCR in some germinal center B cells, as well as some B220 þ cells, and thus frequency of FREB2 expression may be an effect of the individual stimuli driving cellular expansion within tonsillar tissue.
As with FREB1, FREB2 exclusively adopts an intracellular staining pattern when transfected into 293T cells. This staining pattern is consistent with localization to the endoplasmic reticulum. It is not yet clear though whether FREB2 is retained within the ER, directed to another intracellular compartment, or whether it is secreted. The structural similarities between FREB1 and FREB2, along with their presence in germinal center B cells, had suggested some inter-related function, whether cooperative or redundant. However, FREB1 and FREB2 expression appears to be mutually exclusive. That would tend to suggest that complete redundancy between the two molecules is unlikely. There remain two other possibilities. It could be that FREB1 and FREB2 expression define distinct, sequential steps in the germinal center reaction. Alternatively, their function may be mechanistically similar, but their expression represents parallel pathways of differentiation leading to different outcomes. Without knowing which stimuli induce FREB2 expression, it is impossible to predict which of the above scenarios, if any, are true.
One feature of particular interest is the presence of FREB2 in nonproliferating cells of the germinal center. Clonal expansion of antigen-reactive B cells, affinity maturation of B-cell receptors, and receptor specialization through immunoglobulin isotype switching are all hallmark features of the germinal center reaction. The mechanisms driving these processes, however, require cells to be progressing through the cell cycle. It is intriguing to find that FREB2 expression seems to be restricted to quiescent cells. At this time, we have no data indicating whether FREB2 is functioning within quiescent cells, or whether its expression is a remnant of an earlier differentiation event requiring FREB2. It is conceivable that FREB2 may participate in deactivating those B cells, which could potentially produce autoantibodies, antibodies to benign, nonself antigens, or which are simply unable to compete with neighboring cells for antigen binding. Alternatively, the absence of Ki67 antigen in the nucleus of FREB2 þ cells of the germinal center suggests that FREB2 may be upregulated prior to clonal expansion of B cells.
From an organismal prospective, it is notable that FREB2 may not be restricted to a few subsets of B cells within peripheral lymphoid organs. Human FREB2 transcript was easily amplified from the placenta and kidney in addition to the spleen cDNA. This expression may be a result of circulating leukocytes within the tissue vasculature. If not, this may indicate a role for FREB2 in transporting immunoglobulins or regulating immune complex deposition near epithelial surfaces.
In summary, the molecular cloning and definition of FREB2 adds to an already expansive family of Fc receptor homologs, potentially capable of providing important feedback stimuli to differentiating B cells. The unique features of FREB1 and FREB2 potentially transcend the classical regulatory elements affecting ITAM-and ITIM-bearing receptors and provide a novel mechanism for regulating antibody-dependent cellular activation.
